| Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice J Fareed, D Hoppensteadt, J Walenga, O Iqbal, Q Ma, W Jeske, T Sheikh Clinical pharmacokinetics 42, 1043-1057, 2003 | 173 | 2003 |
| Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients Q Ma, F Vaida, J Wong, CA Sanders, Y Kao, D Croteau, DB Clifford, ... Journal of neurovirology 22, 170-178, 2016 | 145 | 2016 |
| Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients CE Haas, JL Nelsen, K Raghavendran, W Mihalko, J Beres, Q Ma, ... Journal of Trauma and Acute Care Surgery 59 (6), 1336-1344, 2005 | 113 | 2005 |
| Interaction between buprenorphine and atazanavir or atazanavir/ritonavir EF McCance-Katz, DE Moody, GD Morse, Q Ma, R DiFrancesco, ... Drug and alcohol dependence 91 (2-3), 269-278, 2007 | 103 | 2007 |
| Pharmacologic approaches to the treatment of Huntington's disease CS Venuto, A McGarry, Q Ma, K Kieburtz Movement Disorders 27 (1), 31-41, 2012 | 102 | 2012 |
| The blood–brain barrier accessibility of a heparin-derived oligosaccharides C3 Q Ma, B Dudas, M Hejna, U Cornelli, JM Lee, S Lorens, R Mervis, I Hanin, ... Thrombosis research 105 (5), 447-453, 2002 | 74 | 2002 |
| CNS neurotoxicity of antiretrovirals T Lanman, S Letendre, Q Ma, A Bang, R Ellis Journal of Neuroimmune Pharmacology 16, 130-143, 2021 | 73 | 2021 |
| Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors Q Ma, OO Okusanya, PF Smith, R DiCenzo, JC Slish, LM Catanzaro, ... Expert opinion on drug metabolism & toxicology 1 (3), 473-485, 2005 | 67 | 2005 |
| Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naïve HIV-infected individuals Y Zhuang, X Qiu, L Wang, Q Ma, M Mapstone, A Luque, M Weber, ... Journal of neurovirology 23, 704-712, 2017 | 64 | 2017 |
| Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile J Fareed, D Hoppensteadt, C Schultz, Q Ma, MF Kujawski, H Messmore Current pharmaceutical design 10 (9), 983-999, 2004 | 64 | 2004 |
| Pharmacogenomics of CYP3A: considerations for HIV treatment SS Lakhman, Q Ma, GD Morse Pharmacogenomics 10 (8), 1323-1339, 2009 | 56 | 2009 |
| CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients J Chen, J Sun, Q Ma, Y Yao, Z Wang, L Zhang, L Li, F Sun, H Lu Therapeutic drug monitoring 32 (5), 573-578, 2010 | 50 | 2010 |
| Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV Q Ma, D Brazeau, BS Zingman, RC Reichman, MA Fischl, BM Gripshover, ... Future Medicine Ltd 8 (3), 227-235, 2007 | 47 | 2007 |
| Therapeutic drug monitoring in highly active antiretroviral therapy X Liu, Q Ma, F Zhang Expert opinion on drug safety 9 (5), 743-758, 2010 | 46 | 2010 |
| Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection J Wang, H Kou, Q Fu, Y Han, Z Qiu, L Zuo, Y Li, Z Zhu, M Ye, Q Ma, T Li PloS one 6 (10), e26739, 2011 | 45 | 2011 |
| Heparin oligosaccharides as potential therapeutic agents in senile dementia Q Ma, U Cornelli, I Hanin, WP Jeske, RJ Linhardt, JM Walenga, J Fareed, ... Current pharmaceutical design 13 (15), 1607-1616, 2007 | 44 | 2007 |
| Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine KY Smith, C Tierney, K Mollan, CS Venuto, C Budhathoki, Q Ma, ... Clinical infectious diseases 58 (4), 555-563, 2014 | 41 | 2014 |
| Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis J Fareed, Q Ma, M Florian, J Maddineni, O Iqbal, DA Hoppensteadt, ... Seminars in thrombosis and hemostasis 30 (S 1), 89-104, 2004 | 41 | 2004 |
| The impact of herbal drug use on adverse drug reaction profiles of patients on antiretroviral therapy in Zimbabwe T Mudzviti, CC Maponga, S Khoza, Q Ma, GD Morse AIDS Research and Treatment 2012, 2012 | 40 | 2012 |
| Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir CD Malvestutto, Q Ma, GD Morse, JA Underberg, JA Aberg JAIDS Journal of Acquired Immune Deficiency Syndromes 67 (4), 390-396, 2014 | 39 | 2014 |
Walter JeskeProfessor of Thoracic & CV Surgery, Loyola University ChicagoVerified email at lumc.edu
